In northern Minnesota, many worry what will happen if their local utility is swallowed up by BlackRock’s business kingdom. As energy expert Scott Hempling told the Minnesota PUC, the deal would make ...

A study of people with diabetes found the risk of macular degeneration remained low, but was 0.2% in people taking GLP-1s, 0.1% in those who didn't. Skip to Main Content Manage alerts for this article ...

Wegovy and other GLP-1 obesity and blood sugar control drugs accounted for 17% of pharmacy benefits spending at CBIZ employer clients with self-funded health plans in 2024, up from 13% in 2023 ...

The report found that just over 2% of adults in the U.S. took a GLP-1 to treat obesity or overweight in 2024, up from just 0.3% in 2019. This is a relative increase of 586.7%, according to the ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related cancers, especially colorectal cancer, according to data released on Thursday ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related cancers, especially colorectal cancer, according to data released on ...

Doctors explain the research behind taking a GLP-1 for PCOS treatment and why these drugs may bring relief from hormonal symptoms in some people.

“As GLP-1s can cross the blood-brain barrier and have a direct effect on brain function, it is important to examine their impact on mental health, especially in patients with mental illness.” ...

SAN DIEGO — Bariatric surgery and GLP-1s conferred similar outcomes in mortality, adverse cardiovascular events and cirrhosis development in patients with diabetes, obesity and metabolic ...

Patients who received GLP-1RAs and/or thiazolidinedione (n=120,877) or did not receive GLP-1RAs or thiazolidinedione (n=486,183) were matched in a 1:1 ratio for final cohorts of 110,411 patients each.

When GLP-1 drugs rapidly gained popularity, tripling in use among adults that don’t have diabetes from 2018 to 2022, the Food and Drug Administration (FDA) ran into supply issues.

GLP-1 receptor agonists have proven to be effective for weight loss but “we don’t know what the long-term outcomes are of targeting this risk factor . . . in terms of secondary prevention of atrial ...